Stocks Health care CTSO
NASDAQ · Health careCytosorbents Corp (CTSO)
Cytosorbents Corp brought in $37.2M of revenue over the twelve months to June 30, 2026, up 3.1% from a year earlier. It posted a net loss of $18.2M. In fiscal 2025 capital spending exceeded operating cash flow by $12.5M. At June 30, 2026 it held $4.4M in cash against $17.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Cytosorbents Corp
- Net worth
- Cytosorbents Corp has a market value (market cap) of $335.6M at the latest share price, and shareholders' equity of -$751K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $37.1M (+4.1% year on year), with a net loss of $8.2M. Over the 12 months to June 30, 2026: revenue $37.2M, net loss $18.2M.
- Cash flow
- In fiscal 2025 operations used $12.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cytosorbents Corp's next report was expected around October 30, 2026 and is not on file with the SEC yet.
What Cytosorbents Corp does
Cytosorbents Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker CTSO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $37.1M | -$8.2M | -$0.13 | -$12.5M |
| 2024 | $35.6M | -$20.7M | -$0.38 | -$14.7M |
| 2023 | $31.1M | -$29.2M | -$0.65 | -$22.2M |
| 2022 | $34.7M | -$32.8M | -$0.75 | -$34.3M |
| 2021 | $43.2M | -$24.6M | -$0.57 | -$17.6M |
| 2020 | $41M | -$7.8M | -$0.20 | -$6.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CTSO ranks in Health care
Latest SEC filings
What Cytosorbents Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026
- September 8, 2026
- August 14, 2026
- August 7, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was flat at $9.6M versus the same quarter last year; diluted EPS -$0.07 versus $0.03.
- July 6, 2026
- June 25, 2026
- June 25, 2026Additional proxy material DEFA14A
- June 25, 2026Proxy statement DEF 14A
Insider trades
What the people running Cytosorbents Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $120.4K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Sobel Alan D.Director | Bought | 1,900 | $11.6K |
| September 15, 2026 | Sobel Alan D.Director | Bought | 500 | $3K |
| September 15, 2026 | Sobel Alan D.Director | Bought | 100 | $601 |
| September 15, 2026 | Chan Phillip P.Chief Executive Officer, Director | Bought | 3,774 | $22.6K |
| September 14, 2026 | Capponi VincentPresident and COO | Bought | 1,800 | $10.9K |
| September 14, 2026 | Capponi VincentPresident and COO | Bought | 273 | $1.6K |
| September 4, 2026 | Chan Phillip P.Chief Executive Officer, Director | Bought | 200,000 | $70K |
| June 15, 2026 | Mariani Peter JChief Financial Officer | Bought | 100,000 | $44K |
Who owns CTSO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Avenir Corp13G, passive with 1 related filers | 8.3% | February 13, 2026 |
| Thomas A. Satterfield, Jr.13G, passive | 6.56% | January 17, 2025 |
| Avenue Capital Management II, L.P.13G, passive with 7 related filers | 5.7% | May 28, 2025 |
Largest institutional holders
Insiders
4 insiders reported holding 789,383 shares in total, about $4.2M at the last price.
| Holder | Shares |
|---|---|
| Mariani Peter JChief Financial Officer | 638,113 |
| Chan Phillip P.Chief Executive Officer, Director | 100,996 |
| Capponi VincentPresident and COO | 40,387 |
| Sobel Alan D.Director | 9,887 |
Questions about CTSO
What does Cytosorbents Corp do?
Cytosorbents Corp is a company in the Health care sector, listed on NASDAQ as CTSO. Its shares trade on NASDAQ under the ticker CTSO.
What is Cytosorbents Corp's net worth?
Cytosorbents Corp has a market value (market cap) of $335.6M at the latest share price, and shareholders' equity of -$751K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cytosorbents Corp profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $18.2M on revenue of $37.2M.
How much revenue does Cytosorbents Corp make?
Over the twelve months to June 30, 2026 Cytosorbents Corp reported revenue of $37.2M. That is 3.1% more than a year earlier.
When did Cytosorbents Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 23, 2026.
When is Cytosorbents Corp's next earnings report?
Cytosorbents Corp's next report was expected around October 30, 2026 and is not on file with the SEC yet.
Similar companies
Compare CTSO with
Follow CTSO
Get an email when Cytosorbents Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cytosorbents Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.